This inventor holds 1 USPTO granted patent and 1 published patent application and 2 EPO patents. Top assignee: University College Dublin. Active years: 2013.
Company Filing History:
Years Active: 2013
Title: Shane Gannon: Innovator in Psycho-Pharmaceuticals
Introduction
Shane Gannon is a notable inventor based in Galway, Ireland. He has made significant contributions to the field of psycho-pharmaceuticals, focusing on innovative treatments for mental health disorders. His work aims to address the pressing issues of anxiety and depression, which affect millions worldwide.
Latest Patents
Shane Gannon holds a patent for a selective Sigma 1 or Dopamine D3 receptor agonist or a 5HT2c receptor ligand. This invention is particularly useful in treating symptoms of anxiety and/or depression associated with affective disorders and cognitive impairment disorders. His patent includes diphenhydramine derivatives of Formula (I), specifically the compound (2-[(4-butylsulfanylphenyl)-phenyl-methyl]sulfanyl-N,N-dimethyl-ethanamin), known as Captodiamine. This innovative approach has the potential to improve the quality of life for many individuals suffering from these conditions.
Career Highlights
Shane Gannon is affiliated with University College Dublin, where he continues to advance his research in psycho-pharmaceuticals. His dedication to innovation in this field has positioned him as a key figure in the development of new therapeutic options.
Collaborations
Shane collaborates with esteemed colleagues, including Ciaran M Regan and Lisa Conboy, who contribute to his research efforts. Their combined expertise enhances the potential impact of their work in the field of mental health.
Conclusion
Shane Gannon's contributions to psycho-pharmaceuticals represent a significant advancement in the treatment of mental health disorders. His innovative patent and collaborative efforts highlight the importance of research in developing effective therapies.